Figure 2.

In vivo mouse immunogenicity of RBD-J adjuvanted with aluminum salt and CpG adjuvants. (a) BALB/c mice (n = 9) were given a subcutaneous primary vaccination on day 0 and boosted on day 21 with 5 mcg RBD-J in various combinations with aluminum salt and CpG adjuvants. Sera were collected on day 21, 35, and 65. (b) anti-RBD-J IgG titer for each formulation group and (c) Pseudovirus neutralization titers (NT₅₀) for AH+CpG group on day 21, 35, and 65. All NT₅₀ values were determined using a best-fit nonlinear regression on serum dilution curves. The dashed lines represent group mean and the errors bars indicate standard deviation. Significance between time-points was determined using Kruskal–Wallis test and post hoc Dunn’s multiple comparisons test (*p ≤ 0.05; **p ≤ 0.0; ***p ≤ 0.001; ****p ≤ 0.0001). Illustration in (a) was created with Biorender.com.